Emerging data support the use of glucagon-like-peptide-1 receptor agonists (GLP-1 RAs) in reducing AF recurrence post-CA, particularly in patients with type 2 diabetes and obesity [173]. This evidence concerns the gene GLP1R and obesity disorder.